ISSN: 1859 - 2872
Case report: Rituximab treatment in a patient with refractory pemphigus vulgaris
Main Article Content
Keywords
Abstract
Pemphigus vulgaris is a group of autoimmune diseases, caused by autoantibodies against the interspinous bridge, causing acanthosis in the epidermis, that creating painful shallow, easily ruptured blisters, crusting, and may be accompanied by mucosal damage. Rituximab is a chimeric monoclonal anti-CD20 antibody that reduces the number of B lymphocytes, downregulates autoantibody producing, this is the first biologic drug licensed for pemphigus treatment. The drug is well tolerated and has amazing treatment effects, especially in patients with treatment - resistant pemphigus vulgaris. A case report: A female patient who was diagnosed with pemphigus vulgaris who underwent many hospitalizations for treatment in 2 years with systemic corticosteroids and immunosuppressive drugs but the disease responded poorly, and experienced many side effects of the medication. The patient was prescribed rituximab at a dosage of 1 gram at weeks 0 and 2. Clinical images were recorded at the time before treatment, after 1 month and 3 months, showing that the patient achieve complete remission. Conclusion: Rituximab is considered a promising new management of pemphigus in general and pemphigus vulgaris in particular. This drug is well tolerated and achieves rapid clinical response.
Article Details
References
2. Schmidt E, Kasperkiewicz M, Joly P (2019) Pemphigus. Lancet 394: 882-894.
3. Joly P, Horvath B, Patsatsi Α, Uzun S, Bech R, Beissert S, Bergman R, Bernard P, Borradori L, Caproni M, Caux F, Cianchini G, Daneshpazhooh M, De D, Dmochowski M, Drenovska K, Ehrchen J, Feliciani C, Goebeler M, Groves R, Guenther C, Hofmann S, Ioannides D, Kowalewski C, Ludwig R, Lim YL, Marinovic B, Marzano AV, Mascaró JM Jr, Mimouni D, Murrell DF, Pincelli C, Squarcioni CP, Sárdy M, Setterfield J, Sprecher E, Vassileva S, Wozniak K, Yayli S, Zambruno G, Zillikens D, Hertl M, Schmidt E (2020) Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 34(9):1900-1913. doi: 10.1111/jdv.16752.
4. Bộ Y tế (2023) Hướng dẫn Chẩn đoán và điều trị các bệnh da liễu, ban hành 11/2023.
5. Chambers SA, Isenberg D (2005) Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 14(3): 210-214.
6. Hanif N, Anwer F (2022) Rituximab. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
7. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P (2007) Treatment of severe pemphigus with rituximab. Arch Dermatol 143(8).
8. Salopek TG, Logsetty S, Tredget EE (2002) Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 47(5): 785-788.
9. Herrmann G, Engert A, Hunzelmann N (2003) Treatment of pemphigus vulgaris with antiCD20 monoclonal antibody (rituximab). Br J Dermatol 148(3): 602-603.
10. Cooper HL, Healy E, Theaker JM et al (2003) Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol 28(4): 366-368.
11. Dupuy A, Viguier M, Bedane C et al (2004) Treatmen to frefractorypemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 140(1): 91-96.
Article Sidebar
